Infliximab for Inflammatory Bowel Disease in Denmark 1999-2005: Clinical Outcome and Follow-Up Evaluation of Malignancy and Mortality

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 11, 2008, Pages 1212-1217

  Caspersen, Sarah ^a   Elkjaer, Margarita ^a   Riis, Lene ^a   Pedersen, Natalia ^a   Mortensen, Christian ^a   Jess, Tine ^b   Sarto, Pernille ^c   Hansen, Tanja S ^a   Wewer, Vibeke ^a   Bendtsen, Flemming ^a   Moesgaard, Flemming ^a   Munkholm, Pia ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b The Capital Region   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AZATHIOPRINE; INFLIXIMAB; METHOTREXATE; PARACETAMOL; STEROID;

ABDOMINAL ABSCESS; ABSCESS; ACUTE HEART INFARCTION; ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; AUTOIMMUNE HEPATITIS; AXILLAE ABSCESS; BONE INFECTION; CANCER RELAPSE; CHILD; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CROHN DISEASE; DEEP VEIN THROMBOSIS; DEMYELINATING DISEASE; DENMARK; DEPRESSION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INFUSION; DRUG SAFETY; EDEMA; ENTERITIS; ERYTHEMA NODOSUM; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INGUINAL ABSCESS; KERATOCONJUNCTIVITIS; LEUKOCYTOCLASTIC VASCULITIS; LUNG EMBOLISM; LUPUS VULGARIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; MYCOSIS; NEUROMUSCULAR DISEASE; OSTEOMYELITIS; PANCREATITIS; PARESTHESIA; PERIANAL ABSCESS; PERITONSILLAR ABSCESS; PLEURISY; PNEUMONIA; POLYNEUROPATHY; POPULATION RESEARCH; RISK ASSESSMENT; SCHOOL CHILD; SEPSIS; SERUM SICKNESS; SHORT TERM MEMORY; SIDE EFFECT; SKIN ABSCESS; TOOTH ABSCESS; TREATMENT OUTCOME; TUBERCULOSIS; ULCERATIVE COLITIS; VISION; VULVAR ABSCESS; WOUND HEALING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CHILD; COHORT STUDIES; DENMARK; FEMALE; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; INTESTINAL NEOPLASMS; MALE; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 55149124689     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2008.05.010     Document Type: Article

References (29)

1. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
2. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
3. Ljung T., Karlen P., Schmidt D., et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 53 (2004) 849-853
4. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
5. Sands B.E., Blank M.A., Patel K., et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2 (2004) 912-920
6. Targan S.R., Hanauer S.B., Van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997) 1029-1035
7. Lawson M.M., Thomas A.G., and Akobeng A.K. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 3 (2006) CD005112
8. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
9. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
10. Warris A., Bjorneklett A., and Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 344 (2001) 1099-1100
11. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4 (2006) 621-630
12. Thomas Jr. C.W., Weinshenker B.G., and Sandborn W.J. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis 10 (2004) 28-31
13. Chung E.S., Packer M., Lo K.H., et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
14. Brown S.L., Greene M.H., Gershon S.K., et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46 (2002) 3151-3158
15. Mackey A.C., Green L., Liang L.C., et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44 (2007) 265-267
16. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
17. Cohen R.D., Tsang J.F., and Hanauer S.B. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 95 (2000) 3469-3477
18. Jess T., Winther K.V., Munkholm P., et al. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 19 (2004) 287-293
19. Jess T., Winther K.V., Munkholm P., et al. Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology 122 (2002) 1808-1814
20. Winther K.V., Jess T., Langholz E., et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2 (2004) 1088-1095
21. Winther K.V., Jess T., Langholz E., et al. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 125 (2003) 1576-1582
22. Ricart E., Panaccione R., Loftus E.V., et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 96 (2001) 722-729
23. Farrell R.J., Shah S.A., Lodhavia P.J., et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 95 (2000) 3490-3497
24. Baert F.J., D'Haens G.R., Peeters M., et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116 (1999) 22-28
25. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60 (2005) 800-805
26. Biancone L., Orlando A., Kohn A., et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 55 (2006) 228-233
27. Jess T., Loftus Jr. E.V., Harmsen W.S., et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut 55 (2006) 1248-1254
28. Katz J.A., Antoni C., Keenan G.F., et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 99 (2004) 2385-2392
29. Mahadevan U., Kane S., Sandborn W.J., et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 21 (2005) 733-738